Category Archives: Myocardial Infarction

Social isolation is associated with an increased risk of a cardiovascular event of more than 40%, and of all-cause mortality approaching 50%, new research suggests. "These results are especially important in the current times of social isolation during the coronavirus crisis," Janine Gronewold, PhD, University Hospital in Essen, Germany, told a press briefing. Continue reading →

Background:The impact of electrocardiography (ECG) morphology on clinical outcomes in patients with non-ST segment elevation myocardial infarction (NSTEMI) receiving percutaneous coronary intervention (PCI) is unknown. This study investigated whether different ST morphologies had different clinical outcomes in patients with NSTEMI receiving PCI. Methods:This retrospective study analyzed record-linked data of 362 patients who had received PCI for NSTEMI between January 2008 and December 2010. Continue reading →

Early signs of a heart attack may occur months before the deadly episode, according to experts. The NHS define a heart attack (myocardial infarction or MI) as a serious medical emergency in which the supply of blood to the heart is suddenly blocked, usually by a blood clot. According to Dr Iqbal Malik, Consultant Cardiologist at OneWelbeck, when heart symptoms first start they can be mild, for example you may feel a bit of breathlessness on exertion, chest tightness, indigestion, or even just a reduction in exercise tolerance. Continue reading →

Stratford EMS receives AHA Mission Lifeline Gold Plus Recognition Award STRATFORD, CT, May 19, 2020 Stratford EMS (SEMS) has received the American Heart Associations Mission: Lifeline EMS Gold Plus Award for implementing quality improvement measures for the treatment of patients who experience severe heart attacks. The "Gold Plus" award is Mission Lifelines highest level of recognition for EMS. Every year, more than 250,000 people experience an ST elevation myocardial infarction (STEMI) the deadliest type of heart attack caused by a blockage of blood flow to the heart that requires timely treatment. Continue reading →

Natural disasters are devastating to not only our physical property but also to our health. There have been several studies over the last few decades that have correlated different types of natural disasters with acutemyocardialinfarctions (AMIs) Continue reading →

BACKGROUND: Women are undertreated and have worse clinical outcomes than men after acutemyocardial infarction. It remains uncertain whether the sex disparities in treatments and outcomes persist in the contemporary era and whether they affect all age groups equally Continue reading →

Myocardial Infarction Drugs Market analysis report has recently added by HealthCare Intelligence Markets which helps to make informed business decisions. Continue reading →

The primary purpose of this study was to examine any potential difference in clinical outcomes between transcarotid artery revascularization performed under local anesthesia compared with general anesthesia by utilizing a large national database. The primary outcome of the study was a composite endpoint of postoperative in-hospital stroke, myocardial infarction and mortality following transcarotid artery revascularization for the index procedure. Continue reading →

Background A proposed cause of dyspnea induced by ticagrelor is an increase in adenosine blood levels. Continue reading →

Myocardial Infarction Drug: This report studies the Myocardial Infarction Drug Market with many aspects of the industry like the market size, market status, market trends and forecast, the report also provides brief information of the competitors and the specific growth opportunities with key market drivers. Find the complete Myocardial Infarction Drug Market analysis segmented by companies, region, type and applications in the report. Market Segment by Companies: BioCardia, Inc., Biscayne Pharmaceuticals, Inc., Capricor Therapeutics, Inc., CellProthera, Celyad SA, Compugen Ltd., CSL Limited, Cynata Therapeutics Limited, FibroGen, Inc., Hemostemix Ltd, Human Stem Cells Institute, HUYA Bioscience International, LLC, Immune Pharmaceuticals Inc., Juventas Therapeutics, Inc., Laboratoires Pierre Fabre SA, Lees Pharmaceutical Holdings Limited, LegoChem Biosciences, Inc, and more Get a Free Sample Copy @ https://www.reportsandmarkets.com/sample-request/myocardial-infarction-drug-global-market-status-trend-report-2013-2023-top-20-countries-data?utm_source=3wnews&utm_medium=39 Myocardial Infarction Drug Market continues to evolve and expand in terms of the number of companies, products, and applications that illustrates the growth perspectives. Continue reading →